Patents by Inventor Kevin Karel Florentina Arien

Kevin Karel Florentina Arien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR DESIGNING A DRUG REGIME FOR HIV-INFECTED PATIENTS
    Publication number: 20170198330
    Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.
    Type: Application
    Filed: March 13, 2017
    Publication date: July 13, 2017
    Inventors: KURT VAN BAELEN, LIEVEN JOZEF STUYVER, KEVIN KAREL FLORENTINA ARIEN
  • Triazines with suitable spacers for treatment and/or prevention of HIV infections
    Patent number: 9650348
    Abstract: The present invention relates to the field of HIV-1 infections, and in particular provides novel compounds containing triazine rings and suitable spacers. The compounds according to this invention are very suitable for the prevention and/or treatment of HIV-1 infection and in particular show improved activity against NNRTI-resistant viruses of HIV-1.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: May 16, 2017
    Assignees: Universiteit Antwerpen, Shakturana CV
    Inventors: Jan Heeres, Koen Augustyns, Pieter Van Der Veken, Jurgen Joossens, Venkatraj Muthusamy, Kevin Karel Florentina Arien, Guido Louis Emile Vanham, Paulus Lewi
  • Method for designing a drug regime for HIV-infected patients
    Patent number: 9631220
    Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: April 25, 2017
    Assignee: Janssen Diagnostics BVBA
    Inventors: Kurt Van Baelen, Lieven Jozef Stuyver, Kevin Karel Florentina Arien
  • METHOD FOR DESIGNING A DRUG REGIME FOR HIV-INFECTED PATIENTS
    Publication number: 20150218611
    Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.
    Type: Application
    Filed: February 9, 2015
    Publication date: August 6, 2015
    Inventors: KURT VAN BAELEN, LIEVEN JOZEF STUYVER, KEVIN KAREL FLORENTINA ARIEN
  • Triazines With Suitable Spacers for Treatment And/Or Prevention of HIV Infections
    Publication number: 20150126510
    Abstract: The present invention relates to the field of HIV-1 infections, and in particular provides novel compounds containing triazine rings and suitable spacers. The compounds according to this invention are very suitable for the prevention and/or treatment of HIV-1 infection and in particular show improved activity against NNRTI-resistant viruses of HIV-1.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 7, 2015
    Applicants: Universiteit Antwerpen, Shakturana CV
    Inventors: Jan Heeres, Koen Augustyns, Pieter Van Der Veken, Jurgen Joossens, Venkatraj Muthusamy, Kevin Karel Florentina Arien, Guido Louis Emile Vanham, Paulus Lewi (deceased)
  • Method for designing a drug regime for HIV-infected patients
    Patent number: 8338101
    Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: December 25, 2012
    Assignee: VIRCO BVBA
    Inventors: Kurt Van Baelen, Lieven Jozef Stuyver, Kevin Karel Florentina Ariën
  • METHOD FOR DESIGNING A DRUG REGIME FOR HIV-INFECTED PATIENTS
    Publication number: 20100099078
    Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.
    Type: Application
    Filed: January 23, 2008
    Publication date: April 22, 2010
    Inventors: Kurt Van Baelen, Lieven Jozef Stuyver, Kevin Karel Florentina Arien